skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Onartuzumab (Code C82348)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Onartuzumab

Definition: A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity. Anti-MET monoclonal antibody MetMAb binds to the extracellular domain of c-Met, preventing the binding of its ligand, hepatocyte growth factor (HGF); the activation of the c-Met signaling pathway is thus inhibited, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase, is overexpressed on the cell surfaces of a variety of cancer cell types and may play a key role in their proliferation, invasion and survival.

Display Name: Onartuzumab

Label: Onartuzumab

NCI Thesaurus Code: C82348 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2826110  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-MET Monoclonal Antibody MetMAb
PRO 143966

External Source Codes: 
CAS Registry Number 1133766-06-9 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 639516
PDQ Open Trial Search ID 639516 (check for NCI PDQ open clinical trial info)
UMLS CUI C2826110

Other Properties:
     Name Value (qualifiers indented underneath)
code C82348
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-MET_Monoclonal_Antibody_MetMAb
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom